mk-0893
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2005 (NCT02012166)
Timeline
Indications
Studied for
Mechanism of action
- Glucagon receptorANTAGONIST
GCGR antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc2cc(-c3cc(-c4cc(Cl)cc(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1- Mol. weight
- 588.49 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1933349 ↗
Also known as
- mk0893
- mk0893
- mk-0893
- mk-0893
- mk-0893
- mk-0893
- mk-0893
- n-((4-(1-(3-(3,5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1h-pyrazol-1-yl)ethyl)phenyl)carbonyl)-beta-alanine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00902161 | Phase 1 | May 1, 2009 | Merck |
| NCT00631488 | Phase 2 | Feb 1, 2008 | Merck |
| NCT00479466 | Phase 2 | Jul 1, 2007 | Merck |
| NCT02004886 | Phase 2 | Aug 11, 2006 | Merck |
| NCT02012166 | Phase 1 | Jul 1, 2005 | Merck |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 5 | 5 | 2 | 2005 |
1 organizations
Page 1 / 1